Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

NCT03382600 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Oxaliplatin
DRUG: TS-1
DRUG: Cisplatin

Sponsor

Merck Sharp & Dohme LLC